Q2 FY2027 · ended Sep 30, 2026 · Revenue $336.31M, +22.7% YoY · Filed Nov 5, 2026
Prestige Consumer Healthcare Inc. (PBH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2027, the quarter ended Sep 30, 2026, it reported revenue of $336.3 million and net income of $25.3 million. Free cash flow was $34.2 million. As of Sep 30, 2026 it held $46.5 million in cash and investments and $2.1 billion in total debt.
Revenue
$336.31M
+22.7% vs year-ago quarter
Net income
$25.30M
-40.1% vs year-ago quarter
Operating cash flow
$37.87M
-34.1% vs year-ago quarter
Free cash flow
$34.24M
-38.2% vs year-ago quarter
EPS
$0.53
-38.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
47.40M
-1.4% vs year-ago quarter
Net cash
$-2.08B
Q2 FY2027
Operating margin
25.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBH (NYSE)
- Fiscal year ends
- March 31
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1295947
- Former names
- Prestige Brands Holdings, Inc. (until Aug 10, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2027 Sep 30, 2026 |
Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $336.3M | $265.7M | $281.6M | $283.4M | $274.1M |
| Operating income | $80.7M | $52.5M | $75.5M | $82.5M | $79.7M |
| Net income | $25.3M | $29.2M | $53.9M | $46.7M | $42.2M |
| Diluted EPS | $0.53 | $0.61 | $1.13 | $0.97 | $0.86 |
| Operating cash flow | $37.9M | $70.8M | $42.8M | $78.3M | $57.5M |
| Free cash flow | $34.2M | $67.1M | $37.6M | $75.3M | $55.4M |
| Total assets | $4.7B | $4.6B | $3.5B | $3.5B | $3.4B |
| Total liabilities | $2.8B | $2.7B | $1.6B | $1.7B | $1.6B |
| Stockholders' equity | $1.9B | $1.9B | $1.9B | $1.8B | $1.8B |
| Cash and investments | $46.5M | $89.1M | $63.9M | $62.4M | $119.1M |
| Total debt | $2.1B | $2.1B | $1.0B | $1.1B | $1.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 14, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 15, 2026 | Jul 15, 2026 |
All 1002 Prestige Consumer Healthcare Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.